STOCK TITAN

InspireMD nets about $5.3M in option offering

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

InspireMD, Inc. (NSPR) closed the offering under the underwriters’ fully exercised 30-day option on November 20, 2026. The option covered up to 8,635,846 additional common shares and/or Series L warrants to purchase up to 6,490,384 common shares. The option offering generated approximately $5.3 million in net proceeds after underwriting discounts and before offering expenses.

The company’s November 16, 2026 offering included 7,342,308 common shares, pre-funded warrants to purchase up to 50,350,000 shares, and Series L warrants to purchase up to 43,269,231 shares; it generated approximately $34.9 million in net proceeds after underwriting discounts and before offering expenses. Lake Street Capital Markets, LLC, the representative of the underwriters, notified the company on November 18 that it had elected to exercise the option in full. Securities Transfer Corporation is the warrant agent for the Option Common Warrants.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Option common shares Up to 8,635,846 shares Covered by the option exercised in full; offering closed November 20, 2026
Option warrant shares Up to 6,490,384 common shares Underlying the Option Common Warrants
Option net proceeds Approximately $5.3 million After underwriting discounts and before offering expenses
Initial offering common shares 7,342,308 shares Offering closed November 16, 2026
Initial offering pre-funded warrant shares Up to 50,350,000 shares Underlying the pre-funded warrants in the November 16, 2026 offering
Initial offering Series L warrant shares Up to 43,269,231 shares Underlying the Series L warrants in the November 16, 2026 offering
Initial offering net proceeds Approximately $34.9 million After underwriting discounts and before offering expenses
Option period 30 days Option granted to the underwriters
pre-funded warrants financial
"pre-funded warrants to purchase up to 50,350,000 shares of Common Stock"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Series L warrants financial
"Series L warrants to purchase up to 43,269,231 shares of Common Stock"
automatic shelf registration statement regulatory
"effective automatic shelf registration statement on Form S-3"
An automatic shelf registration statement is a pre-approved filing that companies submit to securities regulators, allowing them to sell new shares or bonds quickly and efficiently when needed. It acts like a standing permit, enabling the company to raise money without going through a lengthy approval process each time, which can be helpful for responding promptly to market opportunities or needs. For investors, it provides transparency about the company's ability to raise funds and signals planning flexibility.
underwriting discounts financial
"after deducting underwriting discounts and before offering expenses"
The portion of a securities offering that underwriters keep as payment for arranging and selling the issue, often expressed as the gap between what the issuer receives and the price paid by public investors. It matters to investors because it reduces the net proceeds the company raises and signals how much institutional middlemen are charging — like a broker’s commission — which can affect a deal’s economics and the degree of dilution for existing shareholders.
warrant agency agreement financial
"pursuant to a warrant agency agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did InspireMD (NSPR) raise from the underwriter option?

The option offering generated approximately $5.3 million in net proceeds, after underwriting discounts and before offering expenses. It closed on November 20, 2026.

What securities were covered by InspireMD’s (NSPR) exercised option?

The option covered up to 8,635,846 common shares and/or Series L warrants to purchase up to 6,490,384 common shares. The underwriters’ representative elected to exercise the option in full, and the related offering closed on November 20, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false 0001433607 0001433607 2026-11-20 2026-11-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported): November 20, 2026

 

InspireMD, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

001-35731   26-2123838
(Commission
File Number)
  (IRS Employer
Identification No.)

 

6303 Waterford District Drive, Suite 215
Miami, Florida
  33126
(Address of Principal Executive Offices)   (Zip Code)

 

(888) 776-6804

(Registrant’s Telephone Number, Including Area Code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   NSPR   The Nasdaq Capital Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

As previously disclosed, on November 16, 2026, InspireMD, Inc. (the “Company”) closed its previously announced offering of (i) 7,342,308 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), and pre-funded warrants to purchase up to 50,350,000 shares of Common Stock, and (ii) accompanying Series L warrants to purchase up to 43,269,231 shares of Common Stock (the “Common Warrants”), pursuant to the Company’s effective automatic shelf registration statement on Form S-3 (File No. 333-286309) previously filed with the Securities and Exchange Commission (the “SEC”), raising approximately $34.9 million in net proceeds after deducting underwriting discounts and before offering expenses. Pursuant to the Underwriting Agreement, dated November 13, 2026 (the “Underwriting Agreement”), by and among the Company and Lake Street Capital Markets, LLC, as representative (the “Representative”) of the several underwriters named therein (collectively, the “Underwriters”), the Underwriters were granted a 30-day option (the “Option”) to purchase up to an additional 8,635,846 shares of Common Stock (the “Option Shares”) and/or Common Warrants to purchase up to 6,490,384 shares of Common Stock (the “Option Common Warrants”) from the Company on the same terms and conditions.

 

On November 18, 2026, the Representative notified the Company that it had elected to exercise the Option in full. The offering of the Option Shares and Option Common Warrants closed on November 20, 2026, raising an additional approximately $5.3 million in net proceeds after deducting underwriting discounts and before offering expenses.

 

The Option Common Warrants will be issued pursuant to a warrant agency agreement, dated as of November 12, 2026, by and between the Company and Securities Transfer Corporation, as warrant agent.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INSPIREMD, INC.
   
Date: November 20, 2026 By: /s/ Marvin Slosman
  Name: Marvin Slosman
  Title: Chief Executive Officer

 

 

 

Filing Exhibits & Attachments

3 documents

Keep reading